Citryll has attracted the attention of Johnson & Johnson and Novartis who have joined a stellar syndicate of investors to back the Dutch biotech’s innovative approach to treating inflammatory diseases.
The Oss-headquartered group has closed an oversubscribed €85m ($90m) series B financing which was co-led by J&J’s venture capital arm...